We would like to revise our current validation method for IHC antibodies.
Recently, we've had a lot discussion and no agreement on "how to" and "to
what extent" you need to validate antibodies which have already undergone
manufacturer's testing for specificity and sensitivity. Should this be
treated in the same manner test are validated in the clinical laboratory?
Testing extensive specimens and slides? Or what is considered enough of
validation for patient testing. I would appreciate it if anyone has a
policy/procedure that they would be willing to share. We would like to
ensure that we are in compliance with the antibody validation process.
G.Deville, Histology Supv.
Delta Pathology, Mid-Louisiana
Box 30113, 211 Fourth Street
Alexandria, LA 71301
Work: (318)473-3943 / (318) 473-3180
Mobile: (318) 729-4203
Pager: (318) 427-5444
Histonet mailing list